Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorSão Paulo-
Autor(es): dc.contributorKaiser Day Hospital-
Autor(es): dc.contributorSanto Andre-
Autor(es): dc.contributorFaculdade de Medicina-
Autor(es): dc.contributorJuiz de Fora-
Autor(es): dc.contributorRio de Janeiro-
Autor(es): dc.contributorPorto Alegre-
Autor(es): dc.contributorUniversidade Federal do Paraná (UFPR)-
Autor(es): dc.contributorCuritiba-
Autor(es): dc.contributorTeresina-
Autor(es): dc.contributorUniversity of Juiz de Fora-
Autor(es): dc.contributorUniversidade Federal de Minas Gerais (UFMG)-
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorTakeda Pharmaceuticals Brazil-
Autor(es): dc.contributorUniversidade Federal da Bahia (UFBA)-
Autor(es): dc.creatorSassaki, Ligia Yukie-
Autor(es): dc.creatorBaima, Julio Pinheiro-
Autor(es): dc.creatorMiszputen, Sender J.-
Autor(es): dc.creatorJunior, Roberto Luiz Kaiser-
Autor(es): dc.creatorFaria, Mikaell Alexandre Gouvea-
Autor(es): dc.creatorCatapani, Wilson R.-
Autor(es): dc.creatorBafutto, Mauro-
Autor(es): dc.creatorScotton, António S.-
Autor(es): dc.creatorZaltman, Cyrla-
Autor(es): dc.creatorGonçalves, Carolina D.-
Autor(es): dc.creatorGuimaraes, Isabella Miranda-
Autor(es): dc.creatorRamos, Hagata S.-
Autor(es): dc.creatorFlores, Cristina-
Autor(es): dc.creatorAmarante, Heda M.B.S.-
Autor(es): dc.creatorNones, Rodrigo Bremer-
Autor(es): dc.creatorParente, José Miguel Luz-
Autor(es): dc.creatorLima, Murilo Moura-
Autor(es): dc.creatorChebli, Júlio Maria-
Autor(es): dc.creatorde Lourdes Abreu Ferrari, Maria-
Autor(es): dc.creatorCampos, Julia F.-
Autor(es): dc.creatorSanna, Maria G.P.-
Autor(es): dc.creatorRamos, Odery-
Autor(es): dc.creatorParra, Rogério Serafim-
Autor(es): dc.creatorda Rocha, Jose J.R.-
Autor(es): dc.creatorFeres, Omar-
Autor(es): dc.creatorFeitosa, Marley R.-
Autor(es): dc.creatorCaratin, Rosana Fusaro-
Autor(es): dc.creatorSenra, Juliana Tosta-
Autor(es): dc.creatorSantana, Genoile Oliveira-
Data de aceite: dc.date.accessioned2025-08-21T17:25:50Z-
Data de disponibilização: dc.date.available2025-08-21T17:25:50Z-
Data de envio: dc.date.issued2022-04-29-
Data de envio: dc.date.issued2022-04-29-
Data de envio: dc.date.issued2021-06-21-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.3748/wjg.v27.i23.3396-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/229037-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/229037-
Descrição: dc.descriptionBACKGROUND Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBDs) with a remission-relapsing presentation and symptomatic exacerbations that have detrimental impacts on patient quality of life and are associated with a high cost burden, especially in patients with moderate-to-severe disease. The Real-world Data of Moderate-to-Severe Inflammatory Bowel Disease in Brazil (RISE BR) study was a noninterventional study designed to evaluate disease control, treatment patterns, disease burden and health-related quality of life in patients with moderate-to-severe active IBD. We report findings from the prospective follow-up phase of the RISE BR study in patients with active UC or CD. AIM To describe the 12-mo disease evolution and treatment patterns among patients with active moderate-to-severe IBD in Brazil. METHODS This was a prospective, noninterventional study of adult patients with active Crohn’s disease (CD: Harvey-Bradshaw Index ≥ 8, CD Activity Index ≥ 220), inadequate CD control (i.e., calprotectin > 200 µg/g or colonoscopy previous results), or active ulcerative colitis (UC: Partial Mayo score ≥ 5). Enrollment occurred in 14 centers from October 2016 to February 2017. The proportion of active IBD patients after 9-12 mo of follow-up, Kaplan-Meier estimates of the time to mild or no activity and a summary of treatment initiation, discontinuation and dose changes were examined. RESULTS The study included 118 CD and 36 UC patients, with mean ± SD ages of 43.3 ± 12.6 and 44.9 ± 16.5 years, respectively. The most frequent drug classes at index were biologics for CD (62.7%) and 5-aminosalicylate derivates for UC patients (91.7%). During follow-up, 65.3% of CD and 86.1% of UC patients initiated a new treatment at least once. Discontinuations/dose changes occurred in 68.1% of CD patients [median 2.0 (IQR: 2-5)] and 94.3% of UC patients [median 4.0 (IQR: 3-7)]. On average, CD and UC patients had 4.4 ± 2.6 and 5.0 ± 3.3 outpatient visits, respectively. The median time to first mild or no activity was 319 (IQR: 239-358) d for CD and 320 (IQR: 288-358) d for UC patients. At 9-12 mo, 22.0% of CD and 20.0% of UC patients had active disease. CONCLUSION Although a marked proportion of active IBD patients achieved disease control within one year, the considerable time to achieve this outcome represents an unmet medical need of the current standard of care in a Brazilian real-world setting.-
Descrição: dc.descriptionDepartment of Internal Medicine Botucatu Medical School at Sao Paulo State University (UNESP) Botucatu-
Descrição: dc.descriptionDepartment of Gastroenterology Escola Paulista de Medicina Sao Paulo São Paulo-
Descrição: dc.descriptionDepartment of Proctology Kaiser Day Hospital, São Jose do Rio Preto-
Descrição: dc.descriptionDepartment of Gastroenterology Faculdade de Medicina do ABC Santo Andre-
Descrição: dc.descriptionDepartment of Gastroenterology Faculdade de Medicina, Goiania 74535-170-
Descrição: dc.descriptionDepartment of Gastroenterology CMIP Centro Mineiro de Pesquisa Juiz de Fora-
Descrição: dc.descriptionDepartment of Internal Medicine Federal University of Rio de Janeiro Rio de Janeiro-
Descrição: dc.descriptionDepartment of Gastroenterology Escola Paulista de Medicina São Paulo-
Descrição: dc.descriptionHospital de Clínicas de Porto Alegre Hospital de Clínicas de Porto Alegre Porto Alegre-
Descrição: dc.descriptionHospital de Clinicas da Universidade Federal do Paraná Hospital de Clinicas da Universidade Federal do Paraná-
Descrição: dc.descriptionGastroenterology Department Hospital Nossa Senhora das Graças Curitiba-
Descrição: dc.descriptionDepartment of General Medicine Universidade Federal do Piauí Teresina-
Descrição: dc.descriptionGastroenterology Hospital Universitario da Universidade Federal do Piaui Teresina-
Descrição: dc.descriptionDepartment of Medicine University Hospital of Federal University of Juiz de Fora, Juiz de Fora, Juiz de Fora-
Descrição: dc.descriptionDepartment of Clinical Medicine Universidade Federal de Minas Gerais, Belo Horizonte-
Descrição: dc.descriptionHospital de Clinicas da Universidade Federal do Paraná Hospital de Clinicas da Universidade Federal do Paraná, Curitiba-
Descrição: dc.descriptionDepartment of Surgery and Anatomy Ribeirao Preto Medical School University of Sao Paulo, Ribeirão Preto-
Descrição: dc.descriptionScientific Affairs Takeda Pharmaceuticals Brazil-
Descrição: dc.descriptionClinical Research Takeda Pharmaceuticals São Paulo-
Descrição: dc.descriptionIBD Unit Federal University of Bahia, Salvador-
Descrição: dc.descriptionDepartment of Internal Medicine Botucatu Medical School at Sao Paulo State University (UNESP) Botucatu-
Formato: dc.format3396-3412-
Idioma: dc.languageen-
Relação: dc.relationWorld Journal of Gastroenterology-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectCrohn’s disease-
Palavras-chave: dc.subjectInflammatory bowel diseases-
Palavras-chave: dc.subjectProspective study-
Palavras-chave: dc.subjectUlcerative colitis-
Título: dc.titleReal-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.